Reprise Biomedical Revenue and Competitors

Reprise Biomedical, Inc. is a Minnesota-based startup focused on commercializing biological medical devices manufactured using a proprietary perfusion decellularization technology that supports cellular integration. Reprise was created in connection with a spin-off from Miromatrix Medical Inc. in June 2019. Through the spin-off, Miromatrix transferred to Reprise two existing FDA 510(k) cleared, commercially available medical devices – MiroMesh® Biologic Matrix and MiroDerm® Biologic Wound Matrix – as well as all acellular medical devices in development. MiroMesh and MiroDerm are derived via perfusion decellularization of the highly vascularized porcine liver. A non-crosslinked surgical matrix, MiroMesh comes in a variety of sizes suited for hernia repair applications. MiroDerm is indicated for the management of wounds, including diabetic foot ulcers, venous ulcers, pressure ulcers, and surgical and trauma wounds.